Latest News - LabCorp
Top Corporates Hub
LabCorp
Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?
10.08.2026 14:44
LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.
PODD's Q2 Earnings Top Estimates, FY'26 Sales View Cut, Stock Down
10.08.2026 13:22
Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.
Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma
10.08.2026 11:00
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesi.
CVS Health Q2 Earnings and Revenues Top Estimates, Stock Climbs
05.08.2026 14:20
CVS beats Q2 earnings and revenue estimates as stronger segment performance lifts results and prompts raised 2026 guidance, sending shares higher.
Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer
04.08.2026 11:00
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche's VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma. The assay helps identify patients who may be eligible for treatment with AstraZeneca's TRUQAP®
Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer
04.08.2026 11:00
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche's VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma. The assay helps identify patients who may be eligible for treatment with AstraZeneca's TRUQAP®
Labcorp (LH) Q2 2026 Earnings Call Transcript
04.08.2026 00:16
Specialty testing and Central Labs fueled revenue growth and margin expansion.
Is DGX Stock Worth Buying After Its Strong 2026 Earnings Momentum?
31.07.2026 14:06
Quest Diagnostics' earnings beat, raised 2026 outlook and broad testing demand support momentum, but valuation, debt and margin pressure temper the buy case.
Labcorp Q2 Earnings Call Highlights
31.07.2026 12:03
Labcorp (NYSE:LH) reported second-quarter 2026 revenue growth, margin expansion and higher adjusted earnings, prompting the laboratory services company to raise the midpoint of its full-year revenue and adjusted EPS guidance. Revenue rose 5.8% year over year to $3.7 billion, while adjusted operatin
Labcorp Holdings Inc. Q2 2026 Earnings Call Summary
31.07.2026 02:20
Moby summary of Labcorp Holdings Inc.'s Q2 2026 earnings call
Labcorp (LH) Q2 2026 Earnings Call Transcript
31.07.2026 01:47
Specialty testing and Central Labs fueled revenue growth and margin expansion.
Labcorp (NYSE:LH) Shares Slide on Q2 Revenue Miss Despite Earnings Beat
30.07.2026 11:42
Labcorp Q2 revenue of $3.73B missed estimates, but EPS beat at $4.99. Stock fell 4.6% pre-market despite raised 2026 guidance.
Labcorp (NYSE:LH) Shares Slide on Q2 Revenue Miss Despite Earnings Beat
30.07.2026 11:42
Labcorp Q2 revenue of $3.73B missed estimates, but EPS beat at $4.99. Stock fell 4.6% pre-market despite raised 2026 guidance.
Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance
30.07.2026 10:50
Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the second quarter ended June 30, 2026 and updated its full-year financial guidance.
Labcorp Holdings (LH) Draws Fresh Earnings Optimism, Is It Still 4% Undervalued?
25.07.2026 03:19
Labcorp Holdings (LH) is in focus after recent commentary highlighted rising analyst optimism ahead of its June 2026 quarter earnings, with expectations for higher revenue and year over year earnings growth. See our latest analysis for Labcorp Holdings. The Labcorp Holdings share price has gained 11.9% over the past month and 17.9% year to date. The 3 year total shareholder return of 43.4% points to sustained interest alongside the more recent pickup in momentum. If you are looking beyond...
Labcorp Prepares to Report Q2 Earnings: What's in the Cards?
22.07.2026 12:37
LH heads into Q2 earnings results with expectations for higher revenues and EPS, as diagnostics, specialty testing and new collaborations drive momentum.
Labcorp Holdings: The Story Has Not Changed Materially
16.07.2026 03:02
Labcorp (LH) stock: rollup strategy, automation-driven cost cuts, and predictable 10% return potential with low risk. See here to know why itâs a buy.
Will Strength in Biotechnology Unit Continue to Drive DHR's Growth?
08.07.2026 15:50
Danaher's Biotechnology segment posts 7% core revenue growth as bioprocessing demand strengthened, even as weaker product demand created headwinds.
3 Mid-Cap Stocks Walking a Fine Line
26.06.2026 10:48
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
2 S&P 500 Stocks for Long-Term Investors and 1 Facing Challenges
10.06.2026 13:53
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.